Table 2 Types and severity of adverse events
From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
| Â | All AEs | SAEs | AEs Leading to discontinuation |
|---|---|---|---|
Any | 338 (168) | 121 (89) | 74 |
Infection | 93 (81) | 47 (42) | 20 |
   Tuberculosisa | 4 (4) | 4 (4) | 3 |
   Other bacterial Infection | 38 (33) | 29 (24) | 10 |
   Viral Infection | 8 (8) | 5 (5) | 1 |
   Opportunistic infectiona | 8 (8) | 3 (3) | 2 |
   Other | 35 (32) | 6 (6) | 4 |
Infusion reactionb | 77 (64) | 15 (15) | 33 |
Dermatological disorders | 40 (33) | 2 (2) | 4 |
Cardiovascular disorders | 22 (20) | 15 (13) | 4 |
RA-related disease manifestations | 17 (16) | 11 (11) | 2 |
Gastrointestinal disorders | 17 (16) | 1 (1) | - |
Respiratory disorders | 11 (10) | 4 (4) | - |
Neurologic disorder | 11 (10) | 1 (1) | 1 |
Non-RA joint manifestations | 8 (8) | 4 (4) | - |
Tumora | 7 (7) | 6 (6) | 5 |
   Benign | 3 (3) | 2 (2) | 2 |
   Malignant | 4 (4) | 4 (4) | 3 |
Traumatic event | 7 (7) | 4 (4) | 1 |
Hematologic disorders | 4 (4) | 4 (4) | 1 |
Psychiatric disorders | 3 (3) | 1 (1) | 2 |
Liver toxicities | 2 (2) | 1 (1) | - |
Other | 19 (16) | 5 (5) | 1 |